Acyclic and cyclic nucleoside phosphonates

Antiviral Drug Strategies

Volumn 50, Issue , 2011, Pages 91-128

  Mackman, Richard L ^a   Cihlar, Tomas ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Bioisosteres; HBV; HCV; HIV; Nucleoside phosphonates; Prodrug; Reverse transcriptase; RNA polymerase

Indexed keywords

EID: 84880604486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527635955.ch5     Document Type: Chapter

References (180)

1. Jones, G.H. and Moffatt, J.G. (1968) The synthesis of 60-deoxyhomonucleoside-60-phosphonic acids. Journal of the American Chemical Society, 90, 5336-5338.
2. Rammler, D.H., Yengoyan, L., Paul, A.V., and Bax, P.C. (1967) Nucleoside phosphonic acids. II. The synthesis of 50-deoxythymidine 50-phosphonic acid and its pyrophosphate derivatives. Biochemistry, 6, 1828-1837.
3. De Clercq, E., Holÿ, A., Rosenberg, I., Sakuma, T., Balzarini, J., and Maudgal, P.C. (1986) A novel selective broadspectrum anti-DNA virus agent. Nature, 323, 464-467.
4. Lee, W.A. and Martin, J.C. (2006) Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Research, 71, 254-259.
5. Hawkins, T., Veikley, W., St Claire, R.L., 3rd, Guyer, B., Clark, N., and Kearney, B.P. (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. Journal of Acquired Immune Deficiency Syndromes, 39, 406-411.
6. Kim, C.U., Luh, B.Y., Misco, P.F., Bronson, J.J., Hitchcock, M.J., Ghazzouli, I., and Martin, J.C. (1990) Acyclic purine phosphonate analogues as antiviral agents: synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 33, 1207-1213.
7. Engel, R. (1977) Phosphonates as analogs of natural phosphates. Chemical Reviews, 1977, 349-367.
8. Holÿ, A. (1967) Synthesis of 50-deoxyuridine 50-phosphonic acid. Tetrahedron Letters, 10, 881-884.
9. De Clercq, E., and Holÿ, A. (2005) Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nature Reviews Drug Discovery, 4, 928-940.
10. Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., and De Clercq, E. (1997) HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry & Chemotherapy, 8, 1-23.
11. Holÿ, A., Votruba, I.,Merta, A., Cernÿ, J., Veselÿ, J., Vlach, J., Sedivä, K., Rosenberg, I., Otmar, M., Hrebabeckÿ, H., Trävnicek, M., Vonka, V., Snoeck, R., and De Clercq, E. (1990) Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virusencoded enzymes in vitro. Antiviral Research, 13, 295-311.
12. Heijtink, R.A., Kruining, J., de Wilde, G.A., Balzarini, J., De Clercq, E., and Schalm, S.W. (1994) Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrobial Agents and Chemotherapy, 38, 2180-2182.
13. Balzarini, J., Holÿ, A., Jindrich, J., Naesens, L., Snoeck, R., Schols, D., and De Clercq, E. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrobial Agents and Chemotherapy, 37, 332-338.
14. Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I., and Holÿ, A. (1988) (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy, 32, 1839-1844.
15. Neyts, J., Snoeck, R., Schols, D., Balzarini, J., and De Clercq, E. (1990) Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology, 179, 41-50.
16. Xiong, X., Smith, J.L., Kim, C., Huang, E.S., and Chen, M.S. (1996) Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochemical Pharmacology, 51, 1563-1567.
17. Xiong, X., Smith, J.L., and Chen, M.S. (1997) Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrobial Agents and Chemotherapy, 41, 594-599.
18. Bidanset, D.J., Rybak, R.J.,Hartline, C.B., and Kern, E.R. (2004) Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue. Antiviral Research, 63, 61-64.
19. Bravo, F.J., Stanberry, L.R., Kier, A.B., Vogt, P.E., and Kern, E.R. (1993) Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Research, 21, 59-72.
20. Stittelaar, K.J., Neyts, J., Naesens, L., van Amerongen, G., van Lavieren, R.F., Holÿ, A., De Clercq, E., Niesters, H.G., Fries, E., Maas, C., Mulder, P.G., van der Zeijst, B.A., and Osterhaus, A.D. (2006) Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature, 439, 745-748.
21. + HSV-1 keratitis in rabbits. Antiviral Research, 16, 93-100.
22. Smith, I.L., Cherrington, J.M., Jiles, R.E., Fuller, M.D., Freeman,W.R., and Spector, S.A. (1997) High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. The Journal of Infectious Diseases, 176, 69-77.
23. Palmer, S.,Margot, N., Gilbert, H., Shaw, N., Buckheit, R., Jr., and Miller, M. (2001) Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. AIDS Research and Human Retroviruses, 17, 1167-1173.
24. Chen, R.Y., Edwards, R., Shaw, T., Colledge, D., Delaney, W.E., 4th, Isom, H., Bowden, S., Desmond, P., and Locarnini, S.A. (2003) Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology (Baltimore, MD), 37, 27-35.
25. Westland, C.E., Yang, H., Delaney, W.E., 4th ,Wulfsohn, M., Lama, N.,Gibbs, C.S., Miller, M.D., Fry, J., Brosgart, C.L., Schiff, E.R., and Xiong, S. (2005) Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients. Journal of Viral Hepatitis, 12, 67-73.
26. Yang, H., Qi, X., Sabogal, A., Miller, M., Xiong, S., and Delaney, W.E., 4th (2005) Cross-resistance testing of nextgeneration nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antiviral Therapy, 10, 625-633.
27. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., and Holÿ, A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Research, 8, 261-272.
28. Snoeck, R., Andrei, G., and De Clercq, E. (1996) Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. European Journal of Clinical Microbiology & Infectious Diseases, 15, 574-579.
29. Xiong, X., Flores, C., Fuller, M.D., Mendel, D.B., Mulato, A.S., Moon, K., Chen, M.S., and Cherrington, J.M. (1997) In vitro characterization of the antihuman cytomegalovirus activity ofPMEA (adefovir). Antiviral Research, 36, 131-137.
30. Lin, J.C., De Clercq, E., and Pagano, J.S. (1987) Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrobial Agents and Chemotherapy, 31, 1431-1433.
31. Merta, A., Votruba, I., Rosenberg, I., Otmar, M., Hrebabeckÿ, H., Bernaerts, R., and Holÿ, A. (1990) Inhibition of herpes simplex virusDNApolymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Research, 13, 209-218.
32. Cernÿ, J., Votruba, I., Vonka, V., Rosenberg, I., Otmar, M., and Holÿ, A. (1990) Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Research, 13, 253-264.
33. Andrei, G., Snoeck, R., Piette, J., Delvenne, P., and De Clercq, E. (1998) Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncology Research, 10, 523-531.
34. Kramata, P., Downey, K.M., and Paborsky, L.R. (1998) Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro. The Journal of Biological Chemistry, 273, 21966-21971.
35. Reiser, H., Wang, J., Chong, L., Watkins, W.J., Ray, A.S., Shibata, R., Birkus, G., Cihlar, T., Wu, S., Li, B., Liu, X., Henne, I.N.,Wolfgang, G.H., Desai, M., Rhodes, G.R., Fridland, A., Lee, W.A., Plunkett, W., Vail, D., Thamm, D.H., Jeraj, R., and Tumas, D.B. (2008) GS-9219: a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin?s lymphoma. Clinical Cancer Research, 14, 2824-2832.
36. Wolfgang, G.H., Shibata, R., Wang, J., Ray, A.S.,Wu, S., Doerrfler, E., Reiser, H., Lee,W.A., Birkus, G., Christensen, N.D., Andrei, G., and Snoeck, R. (2009) GS-9191. is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions. Antimicrobial Agents and Chemotherapy, 53, 2777-2784.
37. Balzarini, J., Holÿ, A., Jindrich, J., Dvorakova, H., Hao, Z., Snoeck, R., Herdewijn, P., Johns, D.G., and De Clercq, E. (1991) 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 88, 4961-4965.
38. Mulato, A.S. and Cherrington, J.M. (1997) Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Research, 36, 91-97.
39. Balzarini, J., Aquaro, S., Perno, C.F., Witvrouw, M., Holÿ, A., and De Clercq, E. (1996) Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochemical and Biophysical Research Communications, 219, 337-341.
40. Shirasaka, T., Chokekijchai, S., Yamada, A., Gosselin, G., Imbach, J.L., and Mitsuya, H. (1995) Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrobial Agents and Chemotherapy, 39, 2555-2559.
41. Miller, M.D., Margot, N.A., Hertogs, K., Larder, B., and Miller, V. (2001) Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides, Nucleotides & Nucleic Acids, 20, 1025-1028.
42. Harrigan, P.R., Miller, M.D., McKenna, P., Brumme, Z.L., and Larder, B.A. (2002) Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrobial Agents and Chemotherapy, 46, 1067-1072.
43. Cherrington, J.M., Allen, S.J.W., Bischofberger, N., and Chen, M.S. (1995) Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners withHIVreverse transcriptase andhumanDNApolymerasesa, b, and c. Antiviral Chemistry & Chemotherapy, 6, 217-221.
44. Meyer, P.R., Matsuura, S.E., So, A.G., and Scott, W.A. (1998) Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 95, 13471-13476.
45. White, K.L., Margot, N.A., Ly, J.K., Chen, J.M., Ray, A.S., Pavelko, M., Wang, R., McDermott, M., Swaminathan, S., and Miller, M.D. (2005) A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS (London, England), 19, 1751-1760.
46. Delaney, W.E., 4th, Ray, A.S., Yang, H., Qi, X., Xiong, S., Zhu, Y., and Miller, M.D. (2006) Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrobial Agents and Chemotherapy, 50, 2471-2477.
47. Gaillard, R.K., Barnard, J., Lopez, V., Hodges, P., Bourne, E., Johnson, L., Allen, M.I., Condreay, P., Miller, W.H., and Condreay, L.D. (2002) Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrobial Agents and Chemotherapy, 46, 1005-1013.
48. Xiong, X., Flores, C., Yang, H., Toole, J.J., and Gibbs, C.S. (1998) Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology (Baltimore, MD), 28, 1669-1673.
49. Cihlar, T., Ho, E.S., Lin, D.C., and Mulato, A.S. (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides & Nucleic Acids, 20, 641-648.
50. Barnard, D.L., Huffman, J.H., Sidwell, R.W., and Reist, E.J. (1993) Selective inhibition of cytomegaloviruses by 9-(30-ethylphosphono-10-hydroxymethyl-10-propyloxy-methyl)guanine. Antiviral Research, 22, 77-89.
51. Smee, D.F., Sugiyama, S.T., and Reist, E.J. (1994) Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrobial Agents and Chemotherapy, 38, 2165-2168.
52. Smee, D.F. and Reist, E.J. (1996) Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate. Antimicrobial Agents and Chemotherapy, 40, 1964-1966.
53. Bridges, C.G., Taylor, D.L., Ahmed, P.S., Brennan, T.M., Hornsperger, J.M., Nave, J.F., Casara, P., and Tyms, A.S. (1996) MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection. Antimicrobial Agents and Chemotherapy, 40, 1072-1077.
54. Yuen, M.F., Lee, S.H., Kang, H.M., Kim, C.R., Kim, J., Ngai,V., and Lai, C.L. (2009) Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrobial Agents and Chemotherapy, 53, 1779-1785.
55. Fung, J., Lai, C.L., and Yuen, M.F. (2008) LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 17, 1581-1588.
56. Balzarini, J., Pannecouque, C., DeClercq, E., Aquaro, S., Perno, C.F., Egberink, H., and Holÿ, A. (2002) Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrobial Agents and Chemotherapy, 46, 2185-2193.
57. De Clercq, E., Andrei, G., Balzarini, J., Leyssen, P., Naesens, L., Neyts, J., Pannecouque, C., Snoeck, R., Ying, C., Hockovä, D., and Holÿ, A. (2005) Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2, 4-diaminopyrimidines. Nucleosides, Nucleotides & Nucleic Acids, 24, 331-341.
58. Herman, B.D., Votruba, I., Holÿ, A., Sluis-Cremer, N., and Balzarini, J. (2010) The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. The Journal of Biological Chemistry, 285, 12101-12108.
59. Hockovä, D., Holÿ, A., Masojidkovä, M., Andrei, G., Snoeck, R., De Clercq, E., and Balzarini, J. (2003) 5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy) ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. Journal ofMedicinal Chemistry, 46, 5064-5073.
60. Ying, C., Holÿ, A., Hockovä, D., Havlas, Z., De Clercq, E., and Neyts, J. (2005) Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities. Antimicrobial Agents and Chemotherapy, 49, 1177-1180.
61. Balzarini, J., Schols, D., Van Laethem, K., De Clercq, E., Hockovä, D., Masojidkovä, M., and Holÿ, A. (2007) Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. The Journal of Antimicrobial Chemotherapy, 59, 80-86.
62. Naesens, L., Lenaerts, L., Andrei, G., Snoeck, R., Van Beers, D., Holÿ, A., Balzarini, J., and De Clercq, E. (2005) Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrobial Agents and Chemotherapy, 49, 1010-1016.
63. Duraffour, S., Snoeck, R., Krecmerova, M., van Den Oord, J., DeVos, R., Holÿ, A., Crance, J.M., Garin, D., De Clercq, E., and Andrei, G. (2007) Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrobial Agents and Chemotherapy, 51, 4410-4419.
64. Andrei, G., Fiten, P., Froeyen, M., De Clercq, E., Opdenakker, G., and Snoeck, R. (2007) DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antiviral Therapy, 12, 719-732.
65. Jie, L., Van Aerschot, A., Balzarini, J., Janssen, G., Busson, R., Hoogmartens, J., De Clercq, E., and Herdewijn, P. (1990) 50-O-Phosphonomethyl-20,30-dideoxynucleosides: synthesis and anti-HIV activity. Journal of Medicinal Chemistry, 33, 2481-2487.
66. Tanaka, H., Fukui, M., Haraguchi, K., Masaki, M., and Miyasaka, T. (1989) Cleavage of a nucleosidic oxetane with carbanions: Synthesis of a highly promising candidate for anti-HIV agents-a phosphonate isostere of AZT 50-phosphate. Tetrahedron Letters, 30, 2567-2570.
67. Freeman, G.A., Rideout, J.L., Miller, W.H., and Reardon, J.E. (1992) 30-Azido-30,50-dideoxythymidine-50-methylphosphonic acid diphosphate: synthesis andHIV-1 reverse transcriptase inhibition. Journal ofMedicinal Chemistry, 35, 3192-3196.
68. Kim, C.U., Bronson, J.J., Ferrara, L.M., and Martin, J.C. (1992) Synthesis and HIV activity of phosphonate isosteres of d4T monophosphate. Bioorganic & Medicinal Chemistry Letters, 2, 367-370.
69. Secrist, J.A., III, Riggs, R.M., Comber, R.N., and Montgomery, J.A. (1992) Synthesis of phosphonate analogs of dideoxyadenosine (ddA)-, dideoxycytosine (ddC)-, dideoxyinosine (ddI)-, and deoxythymidine (ddT) 50-monophosphates.Nucleosides,Nucleotides & Nucleic Acids, 11, 947-956.
70. Mackman, R.L., Zhang, L., Prasad, V., Boojamra, C.G., Douglas, J., Grant, D., Hui, H., Kim, C.U., Laflamme, G., Parrish, J., Stoycheva, A.D., Swaminathan, S.,Wang, K., and Cihlar, T. (2007) Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. Bioorganic and Medicinal Chemistry, 15, 5519-5528.
71. Mackman, R.L., Boojamra, C.G., Prasad, V., Zhang, L., Lin, K.Y., Petrakovsky, O., Babusis, D., Chen, J., Douglas, J., Grant, D., Hui, H.C., Kim, C.U., Markevitch, D.Y., Vela, J., Ray, A., and Cihlar, T. (2007) Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. Bioorganic & Medicinal Chemistry Letters, 17, 6785-6789.
72. Cihlar, T., Ray, A.S., Boojamra, C.G., Zhang, L., Hui, H., Laflamme, G., Vela, J.E., Grant, D., Chen, J., Myrick, F., White, K.L., Gao, Y., Lin, K.Y., Douglas, J.L., Parkin, N.T., Carey, A., Pakdaman, R., and Mackman, R.L. (2008) Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrobial Agents and Chemotherapy, 52, 655-665.
73. Boojamra, C.G., Mackman, R.L., Markevitch, D.Y., Prasad, V., Ray, A.S., Douglas, J., Grant, D., Kim, C.U., and Cihlar, T. (2008) Synthesis and anti-HIV activity of GS-9148 (20-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor. Bioorganic & Medicinal Chemistry Letters, 18, 1120-1123.
74. Tsai, C.H., Doong, S.L., Johns, D.G., Driscoll, J.S., and Cheng, Y.C. (1994) Effect of anti-HIV 20-beta-fluoro-20,30-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochemical Pharmacology, 48, 1477-1481.
75. Lansdon, E.B., Samuel, D., Lagpacan, L., Brendza, K.M., White, K.L., Hung, M., Liu, X., Boojamra, C.G., Mackman, R.L., Cihlar, T., Ray, A.S., McGrath, M.E., and Swaminathan, S. (2010) Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. Journal of Molecular Biology, 397, 967-978.
76. Wu, T., Froeyen, M., Kempeneers, V., Pannecouque, C., Wang, J., Busson, R., De Clercq, E., and Herdewijn, P. (2005) Deoxythreosyl phosphonate nucleosides as selective anti-HIVagents. Journal of the American Chemical Society, 127, 5056-5065.
77. Mackman, R.L., Lin, K.Y., Boojamra, C.G., Hui, H., Douglas, J., Grant, D., Petrakovsky, O., Prasad, V., Ray, A.S., and Cihlar, T. (2008) Synthesis and anti-HIV activity of 20-fluorine modified nucleoside phosphonates: analogs of GS-9148. Bioorganic & Medicinal Chemistry Letters, 18, 1116-1119.
78. Kim, C.U., Luh, B.Y., and Martin, J.C. (1992) Synthesis and anti-HIV activity of 9-[(2R,5R)-2,5-dihydro-5-(phosphonomethoxy)-2-furanyl]-2,6-diaminopurine. Bioorganic & Medicinal Chemistry Letters, 2, 307-310.
79. Bedard, J.,May, S., Lis, M., Tryphonas, L., Drach, J.,Huffman, J., Sidwell, R., Chan, L., Bowlin, T., and Rando, R. (1999) Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrobial Agents and Chemotherapy, 43, 557-567.
80. Bronson, J.J., Ferrara, L.M., Martin, J.C., and Mansuri, M.M. (1992) Synthesis and biological activity of carbocyclic derivatives of the potent antiviral agent 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG). Bioorganic and Medicinal Chemistry, 2, 685-690.
81. Coe, D.M., Roberts, S.M., and Storer, R. (1992) The potential of carbocyclic nucleosides for the treatment of AIDS: synthesis of some diphosphorylphosphonates possessing potent activity against HIV-coded reverse transcriptase. Journal of the Chemical Society, Perkin Transactions 1, 2695-2704.
82. Merlo, V., Reece, F.J., Roberts, S.M., Gregson, M., and Storer, R. (1993) Synthesis of optically active 50-noraristeromycin: enzyme-catalysed kinetic resolution of 9-(4-hydroxycyclopent-2-enyl)purines. Journal of the Chemical Society, Perkin Transactions 1, 1717-1718.
83. Dyatkina, N.B., Theil, F., and Janta-Lipinski, M.V. (1995) Stereocontrolled synthesis of the four stereoisomeric diphosphorylphosphonates of carbocyclic 20,30-dideoxy-20,30-didehydro-50-noradenosine. Tetrahedron, 51, 761.
84. Khandazhinskaya, A.L., Shirokova, E.A., Skoblov, Y.S., Victorova, L.S., Goryunova, L.Y., Beabealashvilli, R.S., Pronyaeva, T.R., Fedyuk, N.V., Zolin, V.V., Pokrovsky, A.G., and Kukhanova, M.K. (2002) Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity. Journal ofMedicinal Chemistry, 45, 1284-1291.
85. Popescu, A., Hornfeldt, A.-B.,Gronowitz, S., and Johansson, N.G. (1994) Synthesis and antiviral activity of some carbocyclic 5-substituted uracil derivatives. Models in Chemistry, 131, 499-511.
86. Boojamra, C.G., Parrish, J.P., Sperandio, D., Gao, Y., Petrakovsky, O.V., Lee, S.K., Markevitch, D.Y., Vela, J.E., Laflamme, G., Chen, J.M., Ray, A.S., Barron, A.C., Sparacino, M.L., Desai, M.C., Kim, C.U., Cihlar, T., and Mackman, R.L. (2009) Design, synthesis, and anti-HIV activity of 40-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry, 17, 1739-1746.
87. Saneyoshi, H., Vu, B.C., Hughes, S.H., Boyer, P.L., Sarafianos, S.G., and Marquez, V.E. (2008) Synthesis of conformationally locked carbocyclic nucleoside phosphonates to probe the active site of HIV-1 RT. Nucleic Acids Symposium Series (Oxford), 52, 623-624.
88. Liboska, R., Masojidkovä, M., and Rosenberg, I. (1996) Carbocyclic phosphonate-based nucleotide analogs related to PMEA II. Racemic cisconfigured derivatives. Collection of Czechoslovak Chemical Communications, 61, 778-790.
89. Norbeck, D.W., Sham, H.L., Rosenbrook, W., Herrin, T., and Plattner, J. (1992) Synthesis and activities of the phosphonate isostere of the monophosphate of cyclobut-G. Nucleosides, Nucleotides & Nucleic Acids, 11, 1383-1391.
90. Guan, H.-P. Qiu, Y.-L., Ksebati, M.B., Kern, E.R., and Zemlicka, J. (2002) Synthesis of phosphonates derivatives of methylenecyclopropane nucleoside analogues by alkylation-elimination method and unusual opening of cyclopropane ring. Tetrahedron, 58, 6047-6059.
91. Onishi, T., Sekiyama, T., and Tsuji, T. (2005) Synthesis of phosphonate analogues of the antiviral cyclopropane nucleoside A-5021. Nucleosides, Nucleotides & Nucleic Acids, 24, 1187-1197.
92. Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins, R.K., and Simon, L.N. (1973)Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proceedings of the National Academy of Sciences of the United States of America, 70, 1174-1178.
93. Fuertes, M., Witkowski, J.T., Streeter, D.G., and Robins, R.K. (1974) Synthesis and enzymatic activity of 1,2,4-triazole-3-carboxamide 60-deoxyhomoribonucleoside-60-phosphonic acid and related compounds. Journal of Medicinal Chemistry, 17, 642-645.
94. Saito, Y., Escuret, V., Durantel, D., Zoulim, F., Schinazi, R.F., and Agrofoglio, L.A. (2003) Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. Bioorganic and Medicinal Chemistry, 11, 3633-3639.
95. Wang, G., Sakthivel, K., Rajappan, V., Bruice, T.W., Tucker, K., Fagan, P., Brooks, J.L., Hurd, T., Leeds, J.M., and Cook, P.D. (2004) Synthesis of azole nucleoside 50-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases. Nucleosides, Nucleotides & Nucleic Acids, 23, 317-337.
96. Boojamra, C.G., Chen, J.M., Huang, A.X., Kim, C.U., Lin, K.-Y., Mackman, R.L., Oare, D.A., Perry, J.K., Saunders, O.L., Swaminathan, S., and Zhang, L. (2008) Antiviral phosphinate compounds. WO2008005542
97. Chen, J.M.,Huang, A.X.,Mackman, R.L., Parrish, J.P., Perry, J.K., Saunders, O.L., and Sperandio, D. (2008) Nucleoside analogs for antiviral treatment. WO2008100447
98. Martin, J.C. and Verheyden, J.P.H. (1988) Synthesis of 40-(hydroxymethyl) guanosine and a phosphonate analogue of guanylic acid.Nucleosides,Nucleotides & Nucleic Acids, 7, 365-374.
99. Koh, Y.H., Shim, J.H., Wu, J.Z., Zhong, W., Hong, Z., and Girardet, J.L. (2005) Design, synthesis, and antiviral activity of adenosine 50-phosphonate analogues as chain terminators against hepatitis C virus. Journal of Medicinal Chemistry, 48, 2867-2875.
100. Mackman, R.L., Boojamra, C.G., Chen, J., Feng, J., Gao, Y., Laflamme, G., Lee, S., Mabery, E., Markevitch, D., Parrish, J., Perry, J., Petrakovsky, O., Ray, A.S., Shih, I.-H., Sperandio, D.,Vela, J., and Cihlar,T. (2008) Synthesis and antiviral activity of 40-modified carbocyclic nucleoside phosphonates. Collection Symposium Series, 10, 191-195.
101. Cundy, K.C., Barditch-Crovo, P., Petty, B.G., Ruby, A., Redpath, M., Jaffe, H.S., and Lietman, P.S. (1999) Clinical pharmacokinetics of 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, 43, 271-277.
102. Wachsman, M., Petty, B.G., Cundy, K.C., Jaffe, H.S., Fisher, P.E., Pastelak, A., and Lietman, P.S. (1996) Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Research, 29, 153-161.
103. Hecker, S.J. and Erion, M.D. (2008) Prodrugs of phosphates and phosphonates. Journal of Medicinal Chemistry, 51, 2328-2345.
104. Mackman, R. and Cihlar, T. (2004) Prodrug strategies in the design of nucleoside and nucleotide antiviral therapeutics. Annual Reports in Medicinal Chemistry, 39, 305-322.
105. Krise, J.P. and Stella, V.J. (1996) Prodrugs of phosphates, phosphonates, and phosphonates. Advanced Drug Delivery Reviews, 19, 287-310.
106. Bischofberger, N.,Hitchcock, M.J., Chen, M.S., Barkhimer, D.B., Cundy, K.C.,Kent, K.M., Lacy, S.A., Lee, W.A., Li, Z.H., Mendel, D.B. et al. (1994) 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrobial Agents and Chemotherapy, 38, 2387-2391.
107. Mendel, D.B., Cihlar, T., Moon, K., and Chen, M.S. (1997) Conversion of 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrobial Agents and Chemotherapy, 41, 641-646.
108. Ho, E.S., Lin, D.C., Mendel, D.B., and Cihlar, T. (2000) Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of humanrenal organic anion transporter 1. Journal of the American Society of Nephrology, 11, 383-393.
109. Robbins, B.L., Srinivas, R.V., Kim, C., Bischofberger, N., and Fridland, A. (1998) Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis (isopropyloxymethylcarbonyl) PMPA. Antimicrobial Agents and Chemotherapy, 42, 612-617.
110. Arimilli, M., Kim, C., and Bischofberger, N. (1997) Synthesis, in vitro biological evaluation, and oral bioavailability of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) prodrugs. Antiviral Chemistry & Chemotherapy, 8, 557-564.
111. Starrett, J.E., Jr., Tortolani, D.R., Russell, J.,Hitchcock, M.J., Whiterock, V.,Martin, J.C., and Mansuri, M.M. (1994) Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Journal of Medicinal Chemistry, 37, 1857-1864.
112. Barditch-Crovo, P., Toole, J., Hendrix, C.W., Cundy, K.C., Ebeling, D., Jaffe, H.S., and Lietman, P.S. (1997) Antihuman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bispivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. The Journal of Infectious Diseases, 176, 406-413.
113. Barditch-Crovo, P., Deeks, S.G., Collier, A., Safrin, S., Coakley, D.F., Miller, M., Kearney, B.P., Coleman, R.L., Lamy, P.D., Kahn, J.O., McGowan, I., and Lietman, P.S. (2001) Phase I/I trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy, 45, 2733-2739.
114. Yuen, M.F., Kim, J., Kim, C.R., Ngai, V., Yuen, J.C., Min, C., Kang, H.M., Shin, B.S., Yoo, S.D., and Lai, C.L. (2006) A randomized placebo-controlled, dosefinding study of oral LB80380 in HBeAgpositive patients with chronic hepatitis B. Antiviral Therapy, 11, 977-983.
115. Yuen, M.F., Han, K.H., Um, S.H., Yoon, S.K., Kim, H.R., Kim, J., Kim, C.R., and Lai, C.L. (2010) Antiviral activity and safety of LB80380 in hepatitis B e antigenpositive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology (Baltimore, MD), 51, 767-776.
116. Benzaria, S., Pelicano, H., Johnson, R., Maury, G., Imbach, J.L., Aubertin, A.M., Obert, G., and Gosselin, G. (1996) Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potentialPMEAprodrugs with improved oral bioavailability. Journal of Medicinal Chemistry, 39, 4958-4965.
117. Lin, C.C., Fang, C., Benetton, S., Xu, G.F., and Yeh, L.T. (2006) Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrobial Agents and Chemotherapy, 50, 2926-2931.
118. Reddy, K.R., Matelich, M.C., Ugarkar, B.G., Gomez-Galeno, J.E., DaRe, J., Ollis, K., Sun, Z., Craigo, W., Colby, T.J., Fujitaki, J.M., Boyer, S.H., van Poelje, P.D., and Erion, M.D. (2008) Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. Journal of Medicinal Chemistry, 51, 666-676.
119. Lin, C.C., Xu, C., Teng, A., Yeh, L.T., and Peterson, J. (2005) Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. Journal of Clinical Pharmacology, 45, 1250-1258.
120. Lin, C., Xu, C., Yeh, L., Sullivan-Bolyai, J., and Xu, Y. (2006) Pharmacokinetics and pharmacodynamics of pradefovir, a livertargeting prodrug of PMEA in HBV patients. Journal of Hepatology, 44, S16.
121. Kamiya, N., Kubota, A., Iwase, Y., Sekiya, K., Ubasawa, M., and Yuasa, S. (2002) Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy, 46, 2872-2877.
122. Ono-Nita, S.K., Kato, N., Shiratori, Y., Carrilho, F.J., and Omata, M. (2002) Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrobial Agents and Chemotherapy, 46, 2602-2605.
123. Sekiya, K., Takashima, H., Ueda, N., Kamiya, N., Yuasa, S., Fujimura, Y., and Ubasawa, M. (2002) 2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents. Journal of Medicinal Chemistry, 45, 3138-3142.
124. Wise, S., Soon, K., Lowe, S., Teng, C., Pan, A., and McGill, J. (2002) A Safety and pharmacodynamic dose ranging study of LY582563 (MCC-478), a novel nucleotide analogue prodrug, in chronic hepatitis B patients. Gastroenterology, 122, 452 (Abs T1360).
125. Hostetler, K.Y. (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Research, 82, A84-A88.
126. Ciesla, S.L., Trahan, J.,Wan,W.B., Beadle, J.R., Aldern, K.A., Painter, G.R., and Hostetler, K.Y. (2003) Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research, 59, 163-171.
127. Quenelle, D.C., Collins, D.J., Pettway, L.R., Hartline, C.B., Beadle, J.R., Wan, W.B., Hostetler, K.Y., and Kern, E.R. (2008) Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. Antiviral Research, 79, 133-135.
128. Quenelle, D.C., Collins, D.J., Wan, W.B., Beadle, J.R., Hostetler, K.Y., and Kern, E.R. (2004) Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrobial Agents and Chemotherapy, 48, 404-412.
129. Parker, S., Touchette, E., Oberle, C., Almond, M., Robertson, A., Trost, L.C., Lampert, B., Painter, G., and Buller, R.M. (2008) Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Research, 77, 39-49.
130. Lanier, R., Lampert, B., Trosta, L., Almonda, M., and Painter, G. (2009) Development of hexadecyloxypropyl tenofovir (CMX157) for HIV: potential for use as a microbicide and therapeutic. 22nd International Conference on Antiviral Research, Abstr 89, Miami Beach, FL, USA.
131. Painter, G.R., Almond, M.R., Trost, L.C., Lampert, B.M., Neyts, J., De Clercq, E., Korba, B.E., Aldern, K.A., Beadle, J.R., and Hostetler, K.Y. (2007) Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrobial Agents and Chemotherapy, 51, 3505-3509.
132. Wyles, D.L., Kaihara, K.A., Korba, B.E., Schooley, R.T., Beadle, J.R., and Hostetler, K.Y. (2009) The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitisCvirus replication in genotype 1A, 1B, and 2A replicons. Antimicrobial Agents and Chemotherapy, 53, 2660-2662.
133. Cahard, D., McGuigan, C., and Balzarini, J. (2004) Aryloxy phosphoramidate triesters as pro-tides. Mini-Reviews in Medicinal Chemistry, 4, 371-381.
134. Cihlar, T. (2008) Amidate prodrugs of nucleoside phosphonates: from design to in vivo proof of concept. Colletion Symposium Series, 10, 45-53.
135. Mackman, R.L., Ray, A.S., Hui, H.C., Zhang, L., Birkus, G., Boojamra, C.G., Desai, M.C., Douglas, J.L., Gao, Y., Grant, D., Laflamme, G., Lin, K.-Y., Markevitch, D.Y., Mishra, R., McDermott, M., Pakdaman, R., Petrakovsky, O.V., Vela, J.E., and Cihlar, T. (2010) Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonates HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorganic and Medicinal Chemistry, 18. (10), 3606-3617.
136. Ballatore, C., McGuigan, C., De Clercq, E., and Balzarini, J. (2001) Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorganic & Medicinal Chemistry Letters, 11, 1053-1056.
137. Lee, W.A., He, G.-X., Eisenberg, E., Cihlar, T., Swaminathan, S., Mulato, A., and Cundy, K.C. (2005) Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrobial Agents and Chemotherapy, 49, 1898-1906.
138. Birkus, G., Wang, R., Liu, X., Kutty, N., MacArthur, H., Cihlar, T., Gibbs, C., Swaminathan, S., Lee, W., and McDermott, M. (2007) Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrobial Agents and Chemotherapy, 51, 543-550.
139. Birkus, G.,Kutty, N.,He, G.X.,Mulato, A., Lee, W., McDermott, M., and Cihlar, T. (2008) Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl] adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Molecular Pharmacology, 74, 92-100.
140. Chou, T.F., Baraniak, J., Kaczmarek, R., Zhou, X., Cheng, J., Ghosh, B., and Wagner, C.R. (2007) Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Molecular Pharmacology, 4, 208-217.
141. Keith, K.A., Hitchcock, M.J., Lee, W.A., Holÿ, A., and Kern, E.R. (2003) Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrobial Agents and Chemotherapy, 47, 2193-2198.
142. Cihlar, T., Laflamme, G., Fisher, R.,Carey, A.C., Vela, J.E., Mackman, R., and Ray, A.S. (2009) Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrobial Agents and Chemotherapy, 53, 150-156.
143. Ray, A.S., Vela, J.E., Boojamra, C.G., Zhang, L., Hui, H., Callebaut, C., Stray, K., Lin, K.Y., Gao, Y.,Mackman, R.L., and Cihlar, T. (2008) Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent. Antimicrobial Agents and Chemotherapy, 52, 648-654.
144. Lalezari, J.P., Stagg, R.J., Kuppermann, B.D., Holland, G.N., Kramer, F., Ives, D.V., Youle, M., Robinson, M.R., Drew, W.L., and Jaffe, H.S. (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Annals of Internal Medicine, 126, 257-263.
145. Lalezari, J.P., Holland, G.N., Kramer, F., McKinley,G.F.,Kemper,C.A., Ives,D.V., Nelson, R., Hardy, W.D., Kuppermann, B.D., Northfelt, D.W., Youle, M., Johnson, M., Lewis, R.A., Weinberg, D.V., Simon, G.L., Wolitz, R.A., Ruby, A.E., Stagg, R.J., and Jaffe, H.S. (1998) Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 17, 339-344.
146. Cihlar, T., Fuller, M.D., and Cherrington, J.M. (1998) Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. Journal of Virology, 72, 5927-5936.
147. Bray, M. and Roy, C.J. (2004) Antiviral prophylaxis of smallpox. The Journal of Antimicrobial Chemotherapy, 54, 1-5.
148. Kahn, J., Lagakos, S., Wulfsohn, M., Cherng, D., Miller, M., Cherrington, J., Hardy, D., Beall, G., Cooper, R., Murphy, R., Basgoz, N., Ng, E., Deeks, S., Winslow, D., Toole, J.J., and Coakley, D. (1999) Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. The Journal of the American Medical Association, 282, 2305-2312.
149. Marcellin, P., Chang, T.T., Lim, S.G., Tong, M.J., Sievert, W., Shiffman, M.L., Jeffers, L., Goodman, Z.,Wulfsohn, M.S., Xiong, S., Fry, J., and Brosgart, C.L. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. The New England Journal of Medicine, 348, 808-816.
150. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z.,Wulfsohn, M.S., Xiong, S., Fry, J., and Brosgart, C.L. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. The New England Journal of Medicine, 348, 800-807.
151. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Ma, J., Brosgart, C.L., Borroto-Esoda, K., Arterburn, S., and Chuck, S.L. (2006) Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology, 131, 1743-1751.
152. Peters, M.G., Hann, H.W., Martin, P., Heathcote, E.J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D.F., Sullivan, M., Kleber, K., Ebrahimi, R., Xiong, S., and Brosgart, C.L. (2004) Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 126, 91-101.
153. Schiff, E., Lai, C.L., Hadziyannis, S., Neuhaus, P., Terrault, N., Colombo, M., Tillmann, H., Samuel, D., Zeuzem, S., Villeneuve, J.P., Arterburn, S., Borroto-Esoda, K., Brosgart, C., and Chuck, S. (2007) Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplantation, 13, 349-360.
154. Schiff, E.R., Lai, C.L., Hadziyannis, S., Neuhaus, P., Terrault, N., Colombo, M., Tillmann, H.L., Samuel, D., Zeuzem, S., Lilly, L., Rendina, M., Villeneuve, J.P., Lama, N., James, C., Wulfsohn, M.S., Namini, H., Westland, C., Xiong, S., Choy, G.S., Van Doren, S., Fry, J., and Brosgart, C.L. (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology (Baltimore, MD), 38 1419-1427.
155. Deeks, S.G., Barditch-Crovo, P., Lietman, P.S.,Hwang, F., Cundy, K.C.,Rooney, J.F., Hellmann, N.S., Safrin, S., and Kahn, J.O. (1998) Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrobial Agents and Chemotherapy, 42, 2380-2384.
156. Schooley, R.T., Ruane, P., Myers, R.A., Beall, G., Lampiris, H., Berger, D., Chen, S.S., Miller, M.D., Isaacson, E., and Cheng, A.K. (2002) Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (London, England), 16, 1257-1263.
157. Squires, K., Pozniak, A.L., Pierone, G., Jr., Steinhart, C.R., Berger, D., Bellos, N.C., Becker, S.L., Wulfsohn, M., Miller, M.D., Toole, J.J., Coakley, D.F., and Cheng, A. (2003) Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Annals of Internal Medicine, 139, 313-320.
158. Gallant, J.E., Staszewski, S., Pozniak, A.L., DeJesus, E., Suleiman, J.M., Miller, M.D., Coakley, D.F., Lu, B., Toole, J.J., and Cheng, A.K. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. The Journal of the American Medical Association, 292, 191-201.
159. Arribas, J.R., Pozniak, A.L., Gallant, J.E., Dejesus, E., Gazzard, B., Campo, R.E., Chen, S.S., McColl, D., Holmes, C.B., Enejosa, J., Toole, J.J., and Cheng, A.K. (2008) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. Journal of Acquired Immune Deficiency Syndromes, 47, 74-78.
160. Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo, R.E., Lu, B., McColl, D., Chuck, S., Enejosa, J., Toole, J.J., and Cheng, A.K. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. The New England Journal of Medicine, 354, 251-260.
161. Sax, P.E., Tierney, C., Collier, A.C., Fischl, M.A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N.C., Myers, L., Katzenstein, D., Farajallah, A., Rooney, J.F., Ha, B., Woodward, W.C., Koletar, S.L., Johnson, V.A., Geiseler, P.J., and Daar, E.S. (2009) Abacavir-lamivudine versus tenofoviremtricitabine for initial HIV-1 therapy. The New England Journal ofMedicine, 361, 2230-2240.
162. Johnson, M.A., Gathe, J.C., Jr., Podzamczer, D., Molina, J.M., Naylor, C.T., Chiu, Y.L., King, M.S., Podsadecki, T.J., Hanna, G.J., and Brun, S.C. (2006) A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. Journal of Acquired Immune Deficiency Syndromes, 43, 153-160.
163. Johnson, M., Grinsztejn, B., Rodriguez, C., Coco, J., DeJesus, E., Lazzarin, A., Lichtenstein, K., Wirtz, V., Rightmire, A., Odeshoo, L., and McLaren, C. (2006) 96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (London, England), 20, 711-718.
164. Zolopa, A.R. (2010) The evolution of HIV treatment guidelines: current state-ofthe-art of ART. Antiviral Research, 85, 241-244.
165. Wainberg, M.A., Miller, M.D., Quan, Y., Salomon, H., Mulato, A.S., Lamy, P.D., Margot, N.A., Anton, K.E., and Cherrington, J.M. (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy, 4, 87-94.
166. Weber, J., Chakraborty, B., Weberova, J., Miller, M.D., and Quinones-Mateu, M.E. (2005) Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. Journal of Clinical Microbiology, 43, 1395-1400.
167. Miller, M.D. (2004) K65R, TAMs and tenofovir. AIDS Reviews, 6, 22-33.
168. Szczech, L.A. (2008) Renal dysfunction and tenofovir toxicity in HIV-infected patients. Topics in HIV Medicine, 16, 122-126.
169. Izzedine, H., Hulot, J.S., Vittecoq, D., Gallant, J.E., Staszewski, S., Launay-Vacher, V., Cheng, A., and Deray, G. (2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviralnaive HIV-1-infected patients: data from a double-blind randomized activecontrolled multicentre study. Nephrology, Dialysis, Transplantation, 20, 743-746.
170. Gallant, J.E., Parish, M.A., Keruly, J.C., and Moore, R.D. (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clinical Infectious Diseases, 40, 1194-1198.
171. Rodriguez-Novoa, S., Labarga, P., DAvolio, A., Barreiro, P., Albalate, M., Vispo, E., Solera, C., Siccardi, M., Bonora, S., Di Perri, G., and Soriano, V. (2010) Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS (London, England), 24, 1064-1066.
172. Garcia-Lerma, J.G., Paxton, L., Kilmarx, P.H., and Heneine, W. (2010) Oral preexposure prophylaxis for HIVprevention. Trends in Pharmacological Sciences, 31, 74-81.
173. Cohen, M.S., Kaleebu, P., and Coates, T. (2008) Prevention of the sexual transmission of HIV-1: preparing for success. Journal of the International AIDS Society, 11, 4.
174. Karim, S. and Baxter, C. (2009) Antiretroviral prophylaxis for the prevention of HIV infection: future implementation challenges. HIV Therapy, 3, 3-6.
175. van Bommel, F., Wunsche, T., Schurmann, D., and Berg, T. (2002) Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology (Baltimore, MD), 36, 507-508.
176. Benhamou, Y., Tubiana, R., and Thibault, V. (2003) Tenofovir disoproxil fumarate in patients with HIV and lamivudineresistant hepatitis B virus. The New England Journal of Medicine, 348, 177-178.
177. Nunez, M., Perez-Olmeda, M., Diaz, B., Rios, P., Gonzalez-Lahoz, J., and Soriano, V. (2002) Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS (London, England), 16, 2352-2354.
178. Marcellin, P., Heathcote, E.J., Buti, M., Gane, E., de Man, R.A., Krastev, Z., Germanidis, G., Lee, S.S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas,O.O., Shiffman,M.L., Trinh, H., Washington, M.K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., and Rousseau, F. (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. The New England Journal of Medicine, 359 2442-2455.
179. Heathcote, E.J.,Gane, E., deMan, R., Lee, S., Flisiak, R., Manns, M., Tchernev, K., Kurdas, O.O., Schiffman, M., Marcellin, P., Sorbel, J., Anderson, J., Mondou, E., and Rousseau, F. (2009) Three years of tenofovir disoproxil fumarate (TDF) in HBeAg-positive patients with chronic hepatitis B (Study 102). 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (Abst. 483).
180. Marcellin, P., Buti, M., Krastev, Z., Germanidis, G., Kaita, K., Kotzev, I., Buggisch, P.,Weilert, F., Trinh, H.,Gurel, S., Heathcote, E.J., Sorbel, J., Anderson, J., Mondou, E., and Rousseau, F. (2009) Three years of tenofovir disoproxil fumarate (TDF) in HBeAg-negative patients with chronic hepatitis B (Study 102). 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA (Abst. 481).